Company Info

Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. Kane’s US FDA 510(k) cleared and Health Canada approved revyve®️ product portfolio addresses both biofilms and wound bacteria.